Fitness & Nutrition

Reperio Launches Reperio Pro As Complementary Offering in its Product Roadmap for Next-Generation Biometric Health Screenings

Retrieved on: 
Tuesday, February 27, 2024

Reperio Health , the only provider of at-home and onsite comprehensive health screenings with instant results, announced today the launch of Reperio Professional (Reperio Pro), which now expands the use of the company’s proprietary technology to support a modernized and user-friendly biometric health screening flow.

Key Points: 
  • Reperio Health , the only provider of at-home and onsite comprehensive health screenings with instant results, announced today the launch of Reperio Professional (Reperio Pro), which now expands the use of the company’s proprietary technology to support a modernized and user-friendly biometric health screening flow.
  • The new product is complementary to the self-directed version deployed for at-home biometric health screenings.
  • Reperio Pro offers clinicians and providers access to Reperio’s next-generation mobile app and screening kit for fast and comprehensive biometric health screenings with instant results.
  • With Reperio Pro, we’ve maintained the integrity of the at-home screening flow while developing a complementary iteration for screening professionals out in the field.

Ilant Health achieves HITRUST i1 certification, showing commitment to supporting enterprise partners with robust data protection

Retrieved on: 
Tuesday, February 27, 2024

Ilant Health , a value-based approach to obesity management and cardiometabolic health, today announced its data center and platforms have earned certified status by HITRUST for information security.

Key Points: 
  • Ilant Health , a value-based approach to obesity management and cardiometabolic health, today announced its data center and platforms have earned certified status by HITRUST for information security.
  • HITRUST Implemented, 1-year (i1) Certification demonstrates that the organization’s data center and platforms are leveraging a set of curated controls to protect against current and emerging threats, including cybersecurity challenges.
  • This certification shows our commitment to protecting our members and partners,” said Elina Onitskansky, CEO and co-founder of Ilant Health.
  • Congratulations to Ilant Health for earning HITRUST i1 Certification and demonstrating the operational maturity of their cybersecurity program.”

Asahi Kasei Offers Pharmaceutical Excipient Ceolus™ with Nitrite Concentration of 0.1 ppm or Less

Retrieved on: 
Tuesday, February 27, 2024

To contribute to reducing the risk of potentially carcinogenic nitrosamine impurities in pharmaceuticals and nutritional supplements, Asahi Kasei now offers Ceolus™ microcrystalline cellulose (MCC) with nitrite levels of 0.1 μg/g (ppm) or less.

Key Points: 
  • To contribute to reducing the risk of potentially carcinogenic nitrosamine impurities in pharmaceuticals and nutritional supplements, Asahi Kasei now offers Ceolus™ microcrystalline cellulose (MCC) with nitrite levels of 0.1 μg/g (ppm) or less.
  • In order to reduce potential health hazards due to nitrosamine impurities, Asahi Kasei has succeeded in maintaining the nitrite concentration of Ceolus™ to 0.1 ppm or less (see image).
  • “Controlling the nitrite concentration in our products is an important step to ensure the provision of safer pharmaceuticals and nutritional supplements.
  • For further details on Ceolus™ and its contribution to pharmaceutical safety, please visit our website at https://www.ceolus.com/en/mcc/ .

Global Vitamin B3-B4 Market Analysis Report 2023-2029 Featuring Lonza, Aurorium, Brother Enterprises, Jubilant Ingrevia, Eastman Chemical, Lasons, Glanbia, and Merck Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, February 26, 2024

The "Global Vitamin B3-B4 Market (2023 Edition): Analysis By Vitamin Type (Vitamin B3, Vitamin B4), Formulation (Dry, Liquid), By Application, By Region, By Country: Market Insights and Forecast (2018-2028)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Vitamin B3-B4 Market (2023 Edition): Analysis By Vitamin Type (Vitamin B3, Vitamin B4), Formulation (Dry, Liquid), By Application, By Region, By Country: Market Insights and Forecast (2018-2028)" report has been added to ResearchAndMarkets.com's offering.
  • Emerging trends and growth opportunities in the global Vitamin B3-B4 market are thoroughly examined in the latest research.
  • The report delves into the intricacies of the market during the forecast period of 2024-2029, shining a light on critical market dynamics.
  • These insights offer key stakeholders, business leaders, and other interested parties a strategic edge in the evolving global Vitamin B3-B4 market.

CarelonRx launches digital-first weight management program to aid members in health journeys

Retrieved on: 
Monday, February 26, 2024

Today, CarelonRx announced it will launch a weight management program this spring to provide members support on their weight loss journeys – including those who utilize GLP-1 medications.

Key Points: 
  • Today, CarelonRx announced it will launch a weight management program this spring to provide members support on their weight loss journeys – including those who utilize GLP-1 medications.
  • Behavioral health and social drivers of health screenings will also be incorporated to ensure whole health is at the heart of personalized wellness plans.
  • “At CarelonRx, we want to ease the complexities of weight loss and weight management, and support healthier lifestyles for our members,” said Paul Marchetti, president of CarelonRx.
  • “Our weight management program is unique because it considers a member’s whole health needs, including pharmacy, medical and social drivers of health data, and creates opportunities for care coordination between nutrition and exercise experts, pharmacists, physicians and health plans.”
    For those participants who are prescribed GLP-1 medications to aid in their weight management journeys, the program will feature a GLP-1 companion module that is designed to provide medication management support with a member’s prescribing physician.

NITRAFLEX® KAOS Launches Nationwide Featuring New Ingredient Technologies

Retrieved on: 
Monday, February 26, 2024

NITRAFLEX KAOS will be launching nationwide in both Vitamin Shoppe and Amazon.

Key Points: 
  • NITRAFLEX KAOS will be launching nationwide in both Vitamin Shoppe and Amazon.
  • With ingredients like Dopaphen™, SuperSodium™, and NO3-T® technologies at its core, this formula is a symphony of precision, engineered to elevate both mental and physical prowess.
  • Dopaphen™, a revolutionary ingredient, sets NITRAFLEX KAOS apart from the competition.
  • GAT Sport CEO Charles Moser made the announcement, “NITRAFLEX KAOS Stim and NON-Stim are our most powerfully explosive pre-workouts to date.

The Beachbody Company, Inc. to Change Ticker Symbol to “BODI” on March 4

Retrieved on: 
Friday, February 23, 2024

The Beachbody Company, Inc. (NYSE: BODY) (“BODi” or the “Company”), today announced that its Class A common stock will begin trading on the New York Stock Exchange (“NYSE”) under the new ticker symbol “BODI” prior to the market open on March 4, 2024.

Key Points: 
  • The Beachbody Company, Inc. (NYSE: BODY) (“BODi” or the “Company”), today announced that its Class A common stock will begin trading on the New York Stock Exchange (“NYSE”) under the new ticker symbol “BODI” prior to the market open on March 4, 2024.
  • This will replace the company’s current ticker symbol, “BODY”.
  • This new ticker symbol aligns with the company’s rebrand from Beachbody to BODi, announced on March 9, 2023.
  • The Company’s Class A common stock, par value $0.0001 per share, will continue to be listed on the NYSE and the CUSIP will remain unchanged.

Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science & Practice Conference

Retrieved on: 
Friday, February 23, 2024

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, announced today that the company will present findings from four studies evaluating apraglutide in adults with short bowel syndrome with intestinal failure (SBS-IF), a condition in which they are dependent on parenteral support, during the American Society for Parenteral and Enteral Nutrition (ASPEN) 2024 Nutrition Science & Practice Conference.

Key Points: 
  • Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, announced today that the company will present findings from four studies evaluating apraglutide in adults with short bowel syndrome with intestinal failure (SBS-IF), a condition in which they are dependent on parenteral support, during the American Society for Parenteral and Enteral Nutrition (ASPEN) 2024 Nutrition Science & Practice Conference.
  • ASPEN is being held from March 2-5, 2024, in Tampa, Florida.
  • SBS is a serious and chronic condition where there is diminished absorptive capacity for fluids and/or nutrients, typically resulting from extensive intestinal resection.
  • “These findings continue to deepen our understanding of GLP-2 and the potential of apraglutide to help adult patients with SBS who are dependent on PS, including those with colon-in-continuity.

Sprouts Farmers Market, Inc. Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Thursday, February 22, 2024

Sprouts Farmers Market, Inc. (Nasdaq: SFM) today reported results for the 13-week fourth quarter and 52-week year ending December 31, 2023.

Key Points: 
  • Sprouts Farmers Market, Inc. (Nasdaq: SFM) today reported results for the 13-week fourth quarter and 52-week year ending December 31, 2023.
  • "Our fourth quarter performance demonstrates our continued strength as a leading specialty grocer," said Jack Sinclair, chief executive officer of Sprouts Farmers Market.
  • "Our 2023 results exceeded our original expectations, with solid comparable sales each quarter, positive traffic, accelerating unit growth, and increasing customer engagement.
  • A webcast of the conference call will be available through Sprouts’ investor relations webpage, accessible via the following link .

Carewell Secures $24.7 Million in Series B Funding to Revolutionize Familial Caregiving Experience

Retrieved on: 
Thursday, February 22, 2024

This latest round of funding was led by the principals of MBF Healthcare, with participation from existing investors Sageview Capital and Headline among others.

Key Points: 
  • This latest round of funding was led by the principals of MBF Healthcare, with participation from existing investors Sageview Capital and Headline among others.
  • In addition, the company has made several senior level hires amidst plans to relocate their headquarters to Miami.
  • “Family caregiving is becoming an increasingly more common experience in the U.S. with spouses, children, parents, and even grandchildren having to take on a caregiving role overnight without warning,” said Bianca Padilla, CEO and Founder of Carewell.
  • The funds from the Series B round will fuel Carewell’s growth strategy, bolster the company’s e-commerce technology, and enhance overall customer experience, focusing on improved service and an expanded suite of products.